Advertisement

Mechanisms for Non-eosinophilic Asthma

  • Arihiko KanehiroEmail author
Chapter
Part of the Respiratory Disease Series: Diagnostic Tools and Disease Managements book series (RDSDTDM)

Abstract

Asthma can be broadly subdivided into eosinophilic or non-eosinophilic phenotypes based on the inflammatory cellular patterns seen in sputum, blood, and airway tissue. However, the most appropriate cutoff value of non-eosinophilic asthma that identifies individuals in whom neutrophils are activated and contributing to the pathogenic processes in asthma is not elucidated compared to eosinophilic asthma. Major clinical phenotypes of non-eosinophilic asthma include those patients with neutrophilic, paucigranulocytic, and late-onset obesity-related asthma. The mechanism of non-eosinophilic asthma is very complicated and has not been investigated in detail; nonetheless many potential molecular pathways may be implicated in the development of non-eosinophilic asthma.

The cause of airway neutrophilia in asthma is possibly due to augmented innate immunity, IL-23-Th17-IL-17-ILC3 pathway-mediated neutrophilic inflammation, delayed apoptosis of neutrophils caused by epithelial cell-derived cytokines and growth factors, corticosteroid treatment inducing impaired apoptosis of neutrophils, and ineffective macrophage efferocytosis of neutrophils, upregulated NLRP-3 inflammasome and p38/MAPK activity, and reduced lipoxin levels, as well as an altered airway microbiome. Non-eosinophilic inflammation is associated with an impaired therapeutic response to inhaled corticosteroids and usually results in severe uncontrolled asthma. Better understanding of the mechanisms of non-eosinophilic inflammation in asthma will identify new approaches for the treatment of severe non-eosinophilic asthma patients.

Keywords

Eosinophilic asthma Non-eosinophilic asthma Non-eosinophilic airway inflammation Neutrophilic inflammation Paucigranulocytic inflammation 

Abbreviations

CXCL1

Chemokine ligand 1

CXCR2

Chemokine receptor 2

Cys-LTs

Cysteinyl leukotrienes

ECP

Eosinophil cationic protein

EPO

Eosinophil peroxidase

IFN

Interferon

ILC

Innate lymphoid cell

LT

Leukotriene

MBP

Major basic protein

MMP-9

Matrix metalloproteinase-9

NK cell

Natural killer cell

NKT cell

Natural killer T cell

PGD2

Prostaglandin D2

ROS

Reactive oxygen species

TGF-β

Transforming growth factor-β

TNF-α

Tumor necrosis factor-α

TSLP

Thymic stromal lymphopoietin

References

  1. 1.
    Arron J, Choy D, Laviolette M, Kelsen S, Hatab A, Leigh R. Disconnect between sputum neutrophils and other measures of airway inflammation in asthma. Eur Respir J. 2014;43:627–9.CrossRefGoogle Scholar
  2. 2.
    Hastie AT, Moore WC, Li H, Rector BM, Ortega VE, Pascual RM, National Heart, Lung, and Blood Institute’s Severe Asthma Research Program, et al. Biomarker surrogates do not accurately predict sputum eosinophil and neutrophil percentages in asthmatic subjects. J Allergy Clin Immunol. 2013;132:72–80.CrossRefGoogle Scholar
  3. 3.
    Thomson NC, Chaudhuri R, Heaney L, Bucknall C, Niven R, Brightling C. Clinical outcomes and inflammatory biomarkers in current smokers and exsmokers with severe asthma. J Allergy Clin Immunol. 2013;131:1008–16.CrossRefGoogle Scholar
  4. 4.
    Desai D, Newby C, Symon F, Haldar P, Shah S, Gupta S. Elevated sputum interleukin-5 and submucosal eosinophilia in obese individuals with severe asthma. Am J Respir Crit Care Med. 2013;188:657–63.CrossRefGoogle Scholar
  5. 5.
    McGrath K, Icitovic N, Boushey H, Lazarus S, Sutherland E, Chinchilli V. A large subgroup of mild-to-moderate asthma is persistently noneosinophilic. Am J Respir Crit Care Med. 2012;185:612–9.CrossRefGoogle Scholar
  6. 6.
    Wood L, Baines K, Fu J, Scott H, Gibson P. The neutrophilic inflammatory phenotype is associated with systemic inflammation in asthma. Chest. 2012;142:86–93.CrossRefGoogle Scholar
  7. 7.
    Baines K, Simpson J, Wood L, Scott R, Fibbens N, Powell H. Sputum gene expression signature of 6 biomarkers discriminates asthma inflammatory phenotypes. J Allergy Clin Immunol. 2014;133:997–1007.CrossRefGoogle Scholar
  8. 8.
    Simpson J, Phipps S, Baines K, Oreo K, Gunawardhana L, Gibson P. Elevated expression of the NLRP3 inflammasome in neutrophilic asthma. Eur Respir J. 2014;43:1067–76.CrossRefGoogle Scholar
  9. 9.
    Gao P, Gibson P, Baines K, Yang I, Upham J, Reynolds P. Anti-inflammatory deficiencies in neutrophilic asthma: reduced galectin-3 and IL-1RA/IL-1β. Respir Res. 2015;16:5.CrossRefGoogle Scholar
  10. 10.
    Simpson J, Gibson P, Yang I, Upham J, James A, Reynolds P, et al. Altered sputum granzyme B and granzyme B/proteinase inhibitor-9 in patients with noneosinophilic asthma. Respirology. 2014;19:280–7.CrossRefGoogle Scholar
  11. 11.
    Baines K, Simpson J, Bowden N, Scott R, Gibson P. Differential gene expression and cytokine production from neutrophils in asthma phenotypes. Eur Respir J. 2010;35:522–31.CrossRefGoogle Scholar
  12. 12.
    Fu J, Baines K, Wood L, Gibson P. Systemic inflammation is associated with differential gene expression and airway neutrophilia in asthma. OMICS. 2013;17:187–99.CrossRefGoogle Scholar
  13. 13.
    Cosmi L, Liotta F, Annunziato F. Th17 regulating lower airway disease. Curr Opin Allergy Clin Immunol. 2016;16:1–6.CrossRefGoogle Scholar
  14. 14.
    Ricciardolo FLM, Sorbello V, Folino A, Gallo F, Massaglia GM, Favatà G, et al. Identification of IL-17F/frequent exacerbator endotype in asthma. J Allergy Clin Immunol. 2017;140:395–406.CrossRefGoogle Scholar
  15. 15.
    McKinley L, Alcorn JF, Peterson A, Dupont RB, Kapadia S, Logar A, et al. TH17 cells mediate steroid-resistant airway inflammation and airway hyperresponsiveness in mice. J Immunol. 2008;181:4089–97.CrossRefGoogle Scholar
  16. 16.
    Kim RY, Pinkerton JW, Essilfie AT, Robertson AAB, Baines KJ, Brown AC, et al. Role for NLRP3 inflammasome-mediated, IL-1β-dependent responses in severe, steroid-resistant asthma. Am J Respir Crit Care Med. 2017;196:283–97.CrossRefGoogle Scholar
  17. 17.
    Kuo CS, Pavlidis S, Loza M, Baribaud F, Rowe A, Pandis I, et al. U-BIOPRED Study group. T-helper cell type 2 (Th2) and non-Th2 molecular phenotypes of asthma using sputum transcriptomics in U-BIOPRED. Eur Respir J. 2017;49:1602135.  https://doi.org/10.1183/13993003.02135-2016.CrossRefPubMedGoogle Scholar
  18. 18.
    Simpson JL, Gibson PG, Yang IA, Upham J, James A, Reynolds PN, AMAZES Study Research Group, et al. Impaired macrophage phagocytosis in non-eosinophilic asthma. Clin Exp Allergy. 2013;43:29–35.CrossRefGoogle Scholar
  19. 19.
    Chung KF. p38 mitogen-activated protein kinase pathways in asthma and COPD. Chest. 2011;139:1470–9.CrossRefGoogle Scholar
  20. 20.
    Duvall MG, Barnig C, Cernadas M, Ricklefs I, Krishnamoorthy N, Grossman NL, National Heart Lung, and Blood Institute’s Severe Asthma Research Program-3 Investigators, et al. Natural killer cell-mediated inflammation resolution is disabled in severe asthma. Sci Immunol. 2017;2:eaam5446.  https://doi.org/10.1126/sciimmunol.aam5446.CrossRefPubMedPubMedCentralGoogle Scholar
  21. 21.
    Ono E, Dutile S, Kazani S, Wechsler ME, Yang J, Hammock BD, National Heart, Lung, and Blood Institute’s Asthma Clinical Research Network, et al. Lipoxin generation is related to soluble epoxide hydrolase activity in severe asthma. Am J Respir Crit Care Med. 2014;190:886–97.CrossRefGoogle Scholar
  22. 22.
    Guerra S, Halonen M, Vasquez MM, Spangenberg A, Stern DA, Morgan WJ, et al. Relation between circulating CC16 concentrations, lung function, and development of chronic obstructive pulmonary disease across the lifespan: a prospective study. Lancet Respir Med. 2015;3:613–20.CrossRefGoogle Scholar
  23. 23.
    Hodge S, Hodge G, Simpson JL, Yang IA, Upham J, James A, AMAZES Study Research Group, et al. Blood cytotoxic/inflammatory mediators in non-eosinophilic asthma. Clin Exp Allergy. 2016;46:60–70.CrossRefGoogle Scholar
  24. 24.
    Kim YS, Choi JP, Kim MH, Park HK, Yang S, Kim YS, et al. IgG sensitization to extracellular vesicles in indoor dust is closely associated with the prevalence of non-eosinophilic asthma, COPD, and lung cancer. Allergy, Asthma Immunol Res. 2016;8:198–205.CrossRefGoogle Scholar
  25. 25.
    Jeon SG, Moon HG, Kim YS, Choi JP, Shin TS, Hong SW, et al. 15-lipoxygenase metabolites play an important role in the development of a T-helper type 1 allergic inflammation induced by double-stranded RNA. Clin Exp Allergy. 2009;39:908–17.CrossRefGoogle Scholar
  26. 26.
    Demarche S, Schleich F, Henket M, Paulus V, Van Hees T, Louis R. Detailed analysis of sputum and systemic inflammation in asthma phenotypes: are paucigranulocytic asthmatics really non-inflammatory? BMC Pulm Med. 2016;16:46.CrossRefGoogle Scholar
  27. 27.
    Al-Alwan A, Bates JH, Chapman DG, Kaminsky DA, DeSarno MJ, Irvin CG, et al. The nonallergic asthma of obesity: a matter of distal lung compliance. Am J Respir Crit Care Med. 2014;189:1494–502.CrossRefGoogle Scholar
  28. 28.
    Ather JL, Chung M, Hoyt LR, Randall MJ, Georgsdottir A, Daphtary NA, et al. Weight loss decreases inherent and allergic methacholine hyperresponsiveness in mouse models of diet-induced obese asthma. Am J Respir Cell Mol Biol. 2016;55:176–87.CrossRefGoogle Scholar
  29. 29.
    Kim HY, Lee HJ, Chang YJ, Pichavant M, Shore SA, Fitzgerald KA, et al. Interleukin-17-producing innate lymphoid cells and the NLRP3 inflammasome facilitate obesity-associated airway hyperreactivity. Nat Med. 2014;20:54–61.CrossRefGoogle Scholar

Copyright information

© Springer Nature Singapore Pte Ltd. 2019

Authors and Affiliations

  1. 1.Department of Internal MedicineAllergy and Respiratory Center, Okayama Rosai HospitalOkayamaJapan

Personalised recommendations